16170 Federal Register / Vol. 62, No. 65 / Friday, April 4, 1997 / Notices

best assured of having their full effect if

received by May 5, 1997.

Dated: March 26, 1997.

Martin K. Trusty,

Executive Officer, NIAAA.

[FR Doc. 97–8594 Filed 4–3–97; 8:45 am]

BILLING CODE 4140–01–M

Consensus Development Conference

on Genetic Testing for Cystic Fibrosis

Notice is hereby given of the NIH

Consensus Development Conference on

‘‘Genetic Testing for Cystic Fibrosis,’’

which will be held April 14–16, 1997,

in the Natcher Conference Center of the

National Institutes of Health, 9000

Rockville Pike, Bethesda, Maryland

20892. The conference begins at 8:30

a.m. on April 14, at 8:30 a.m. on April

15, and at 9:00 a.m. on April 16.

At the beginning of this decade, a test

was developed which could identify

individuals who carried the genetic

mutation associated with cystic fibrosis.

Concerned that this test might be

inappropriately or prematurely used, a

number of genetic and health

professional organizations issued

recommendations on its use. These

groups considered the circumstances

under which the tests should be offered

and the populations that would

potentially benefit. In almost every case,

recommendations were made against

using the test for large-scale populationbased screening until more sensitive

tests were developed and more had been

learned about the risks and benefits of

genetic testing for individuals and their

families. Several statements called for

additional support for research on the

educational, laboratory, counseling,

ethical, and cost/benefit issues

associated with the delivery of

population-based screening for cystic

fibrosis. Since that time new research

has yielded a large body of new data on

these issues.

This conference will bring together

the research investigators, health care

providers, epidemiologists, geneticists,

ethicists and other experts, as well as

representatives of the public, to present

and discuss the latest data.

After 11⁄2 days of presentations and

audience discussion, an independent,

non-Federal consensus panel will weigh

the scientific evidence and write a draft

statement that it will present to the

audience on the third day. The

consensus statement will address the

following key questions:

—What is the current state of knowledge

regarding cystic fibrosis natural

history, epidemiology, genotypephenotype correlations, treatment,

and genetic testing in various

populations?

—What has been learned about genetic

testing for cystic fibrosis regarding

(public and health professional)

knowledge and attitudes, interest and

demand, risks and benefits,

effectiveness, cost, and impact?

—Should cystic fibrosis carrier testing

be offered to: (1) individuals with a

family history of cystic fibrosis; (2)

adults in the preconception or

prenatal period; and/or (3) the general

population?

—What are the optimal practices for

cystic fibrosis genetic testing (setting,

timing, and the practices of education,

consent, and counseling)?

—What should be the future directions

for research relevant to genetic testing

for cystic fibrosis and, more broadly,

for research and public policy on

genetic testing?

The primary sponsors of this meeting

are the National Human Genome

Research Institute and the NIH Office of

Medical Applications Research. The

conference is cosponsored by: the

National Institute of Diabetes and

Digestive and Kidney Diseases; the

National Heart, Lung, and Blood

Institute; the National Institute of Child

Health and Human Development; the

NIH Office of Rare Diseases; the

National Institute of Mental Health; the

National Institute of Nursing Research;

the NIH Office of Research on Women’s

Health; the Agency for Health Care

Policy Research; and the Centers for

Disease Control and Prevention.

Advance information on the

conference program and conference

registration materials may be obtained

from: Rose Salton, Technical Resources

International, Inc., 3202 Tower Oaks

Blvd., Suite 200, Rockville, Maryland

20852, (301) 770–3153, confdept@techres.com. The consensus statement will

be submitted for publication in

professional journals and other

publications. In addition, the statement

will be available beginning April 16,

1997 from the NIH Consensus Program

Information Center, P.O. Box 2577,

Kensington, Maryland 20891, phone 1–

888–NIH–CONSENSUS (1–888–644–

2667) and from the NIH Consensus

Program site on the World Wide Web at

http://consensus.nih.gov.

Dated: March 26, 1997.

Ruth L. Kirschstein,

Deputy Director, NIH.

[FR Doc. 97–8593 Filed 4–3–97; 8:45 am]

BILLING CODE 4140–01–M

National Center for Research

Resources; Notice of Meeting of the

National Advisory Research Resources

Council and its Planning

Subcommittee

Pursuant to Pub. L. 92–463, notice is

hereby given of the meeting of the

National Advisory Research Resources

Council (NARRC), National Center for

Research Resources (NCRR). This

meeting will be open to the public as

indicated below. Attendance by the

public will be limited to space available.

This meeting will be closed to the

public as indicated below in accordance

with provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

and sec. 10(d) of Pub. L. 92–463, for the

review, discussion and evaluation of

individual grant applications. The

applications and the discussions could

reveal confidential trade secrets or

commercial property such as patentable

material, and personal information

concerning individuals associated with

the applications, the disclosure of

which would constitute a clearly

unwarranted invasion of personal

privacy.

Ms. Maureen Mylander, Public Affairs

Officer, NCRR, National Institutes of

Health, 1 Rockledge Center, Room 5146,

6705 Rockledge Drive, MSC 7965,

Bethesda, Maryland 20892–7965, (301)

435–0888, will provide a summary of

the meeting and a roster of the members

upon request. Other information

pertaining to the meeting can be

obtained from the Executive Secretary

indicated. Individuals who plan to

attend and need special assistance, such

as sign language interpretation or other

reasonable accommodations, should

contact the Executive Secretary in

advance of the meeting.

Name of Committee: The Subcommittee on

Planning of the National Advisory Research

Resources Council.

Place of Meeting: National Institutes of

Health, 9000 Rockville Pike, Conference

Room D, Natcher Building 45, Bethesda,

Maryland 20892.

Open: May 22, 7:30 a.m.–8:45 a.m.

Purpose/Agenda: To discuss policy issues.

Name of Committee: National Advisory

Research Resources Council.

Place of Meeting: National Institutes of

Health, 9000 Rockville Pike, Conference

Room E1 and E2, Natcher Building 45,

Bethesda, Maryland 20892.

Open: May 22, 9 a.m. until recess.

Closed: May 23, 8:30 a.m. until 9:45 a.m.

Open: May 23, 10:00 a.m. until

adjournment.

Purpose/Agenda: Report of Center Director

and other issues related to Council business.

Executive Secretary: Louise Ramm, Ph.D.,

Deputy Director, National Center for

Research Resources, Building 12A, Room
Federal Register / Vol. 62, No. 65 / Friday, April 4, 1997 / Notices 16171

4011, Bethesda, MD 20892, Telephone: (301)

496–6023.

(Catalog of Federal Domestic Assistance

Program Nos. 93.306, Laboratory Animal

Sciences and Primate Research; 93.333,

Clinical Research; 93.337, Biomedical

Research Support; 93.371, Biomedical

Research Technology; 93.389, Research

Centers in Minority Institutions; 93.198,

Biological Models and Materials Research;

93.167, Research Facilities Improvement

Program; 93.214 Extramural Research

Facilities Construction Projects, National

Institutes of Health)

Dated: March 31, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–8591 Filed 4–3–97; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood

Institute; Notice of Meeting

Pursuant to Pub. L. 92–463, notice is

hereby given of the meeting of the

following National Heart, Lung, and

Blood Institute Special Emphasis Panel.

The meeting will be open to the

public to provide concept review of

proposed contract or grant solicitations.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

inform the Contact Person listed below

in advance of the meeting.

Name of Panel: Standardized Assessment

of Heart Failure in Population Studies.

Dates of Meeting: May 7, 1997.

Time of Meeting: 9:00 a.m.

Place of Meeting: Bethesda, Marriott, 5151

Pooks Hill Road, Bethesda, Maryland 20814.

Agenda: Discussion of standardized

assessment of prevalence, incidence, and

recurrence of heart failure in population

studies for present and future studies.

Contact Person: Robin Boineau, M.D.,

NHLBI/DHVD, Two Rockledge Center, 6701

Rockledge Drive, Rm. 8158, MSC 7934,

Bethesda, Maryland 20892, (301) 435–0455.

(Catalog of Federal Domestic Assistance

Programs Nos. 93.837, Heart and Vascular

Diseases Research; 93.838, Lung Diseases

Research; and 93.839, Blood Diseases and

Resources Research, National Institutes of

Health)

Dated: March 31, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–8586 Filed 4–3–97; 8:45 am]

BILLING CODE 4140–01–M

National Institute on Aging; Notice of

Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Institute on Aging Special

Emphasis Panel meeting:

Name of SEP: Postponed Aging in

Drosophila (Teleconference).

Date of Meeting: March 31, 1997.

Time of Meeting: 2:00 p.m. to adjournment.

Place of Meeting: National Institute on

Aging, Gateway Building, Room 2C212, 7201

Wisconsin Avenue, Bethesda, Maryland

20892.

Purpose/Agenda: To review a program

project.

Contact Person: Dr. James P. Harwood,

Scientific Review Administrator, Gateway

Building, Room 2C212, National Institutes of

Health, Bethesda, Maryland 20892–9205,

(301) 496–9666.

This notice is being published less than 15

days prior to the above meeting due to the

urgent need to meet timing limitations

imposed by the review and funding cycle.

This meeting will be closed in accordance

with the provisions set forth in secs.

552b(c) (4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program No. 93.866, Aging Research,

National Institutes of Health)

Dated: March 31, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–8583 Filed 4–4–97; 8:45 am]

BILLING CODE 4140–01–M

National Institutes of Health

National Institute on Drug Abuse;

Notice of Meeting

Pursuant to Pub. L. 92–463, notice is

hereby given of the meeting of the

National Advisory Council on Drug

Abuse, National Institute on Drug Abuse

on May 13–14, 1997.

On May 13, from 9 a.m. to 4 p.m., the

meeting will be held at the Parklawn

Building, Conference Rooms G and H,

5600 Fishers Lane, Rockville, MD

20857. In accordance with provisions

set forth in secs. 552b(c)(4) and

552b(c)(6), Title 5 U.S.C. and sec. 10(d)

of Pub. L. 92–463, this portion of the

meeting will be closed to the public for

the review, discussion, and evaluation

of grant applications. These applications

and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material

and personal information concerning

individuals associated with the

applications, disclosure of which would

constitute a clearly unwarranted

invasion of personal privacy.

On May 14, from 9 a.m. to 5 p.m., the

meeting will be held at the National

Institutes of Health, Building 31,

Conference Room 10, 9000 Rockville

Pike, Bethesda, Maryland 20892. This

portion of the meeting will be open to

the public for announcements and

reports of administrative, legislative,

and program developments in the drug

abuse field. Attendance by the public

will be limited to space available.

A summary of the meeting and a

roster of committee members may be

obtained from Ms. Camilla L. Holland,

NIDA Committee Management Officer,

National Institutes of Health, Parklawn

Building, Room 10–42, 5600 Fishers

Lane, Rockville, Maryland 20857 (301/

443–2755).

Substantive program information may

be obtained from Dr. Teresa Levitin,

Room 10–42, Parklawn Building, 5600

Fishers Lane, Rockville, Maryland

20857, (301/443–2755).

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

contact the contact person named above

in advance of the meeting.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.277, Drug Abuse

Research Scientist Development and

Research Scientist Awards; 93.278, Drug

Abuse National Research Service Awards for

Research Training; 93.279, Drug Abuse

Research Programs)

Dated: March 31, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–8584 Filed 4–3–97; 8:45 am]

BILLING CODE 4140–01–M

National Institutes of Health

National Institute of Diabetes and

Digestive and Kidney Diseases; Notice

of Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amened (5 U.S.C. Appendix 2), notice is

hereby given of the following National

Institute of Diabetes and Digestive and

Kidney Diseases Special Emphasis

Panel meetings:

Name of SEP: Training Program in

Endocrine and Metabolic Research.

Date: April 15, 1997.

Time: 10:30 AM.

Place: Room 6as–37E, Natcher Building,

NIH, (Telephone Conference Call).

Contact Person: Francisco O. Calvo, Ph.D.,

Chief, Special Emphasis Panel Section,

Review Branch, DEA, NIDDK, Natcher

Building, Room 6as–37E, National Institutes

of Health, Bethesda, Maryland 20892–6600,

Phone: (301) 594–8897.